2
RESEARCH METHODOLOGY
29
5
MARKET OVERVIEW
Monoclonal antibody innovations drive growth amid regulatory challenges and expanding therapeutic opportunities in veterinary care.
53
5.2.1.1
Increasing prevalence of chronic diseases in animals
5.2.1.2
Innovations in monoclonal antibodies targeting infectious diseases
5.2.1.3
Rise in companion animal population and pet ownership
5.2.1.4
Growth in veterinary healthcare expenditure
5.2.2.1
Regulatory hurdles and long approval timelines
5.2.2.2
High cost of development and treatment
5.2.3.1
Expanding therapeutic indications beyond dermatology and osteoarthritis
5.2.3.2
Novel administration routes for monoclonal antibodies
5.2.3.3
Evolving landscape of strategic collaborations and acquisitions
5.2.4.1
Emerging safety concerns and adverse event reporting
5.2.4.2
Limited species-specific knowledge
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4.1
INDICATIVE SELLING PRICE, BY KEY PLAYER
5.4.2
INDICATIVE SELLING PRICE, BY REGION
5.5
SUPPLY CHAIN ANALYSIS
5.7
INVESTMENT AND FUNDING SCENARIO
5.8.1.1
Hybridoma technology
5.8.1.2
Recombinant antibody production
5.8.2
COMPLEMENTARY TECHNOLOGIES
5.8.2.1
Long-acting injectables
5.8.3
ADJACENT TECHNOLOGIES
5.8.3.1
RNA-based therapies
5.9.1
PATENT PUBLICATION TREND
5.9.2
JURISDICTION AND TOP APPLICANT ANALYSIS
5.11
KEY CONFERENCES AND EVENTS, 2025–2026
5.12
REGULATORY LANDSCAPE
5.12.1
REGULATORY FRAMEWORK
5.12.1.5
Middle East & Africa
5.12.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13
PORTER’S FIVE FORCES ANALYSIS
5.13.1
BARGAINING POWER OF SUPPLIERS
5.13.2
BARGAINING POWER OF BUYERS
5.13.3
THREAT OF NEW ENTRANTS
5.13.4
THREAT OF SUBSTITUTES
5.13.5
INTENSITY OF COMPETITIVE RIVALRY
5.14
KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2
KEY BUYING CRITERIA
5.15
UNMET NEEDS/END-USER EXPECTATIONS
5.16
REIMBURSEMENT ANALYSIS
5.18
IMPACT OF AI/GEN AI IN VETERINARY MONOCLONAL ANTIBODIES MARKET
5.18.2
MARKET POTENTIAL OF AI IN VETERINARY MONOCLONAL ANTIBODIES
5.18.4
KEY COMPANIES IMPLEMENTING AI
5.19
IMPACT OF 2025 US TARIFF
5.19.3
PRICE IMPACT ANALYSIS
5.19.4
IMPACT ON COUNTRY/REGION
5.19.5
IMPACT ON END-USE INDUSTRIES
6
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 4 Data Tables
91
6.2.1
INCREASING PREVALENCE OF OSTEOARTHRITIS AND CANINE ATOPIC DERMATITIS TO BOLSTER GROWTH
6.3.1
GROWING RECOGNITION OF OSTEOARTHRITIS IN CATS AND SUCCESSFUL LAUNCH OF SOLENSIA TO FUEL MARKET
7
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 7 Data Tables
97
7.2
LOKIVETMAB (CYTOPOINT)
7.2.1
INCREASING PREVALENCE OF ATOPIC DERMATITIS IN DOGS TO PROMOTE GROWTH
7.3
BEDINVETMAB (LIBRELA)
7.3.1
NEED FOR BETTER PAIN MANAGEMENT SOLUTIONS TO EXPEDITE GROWTH
7.4
FRUNEVETMAB (SOLENSIA)
7.4.1
ABILITY TO IMPROVE MOBILITY AND COMFORT IN AGING CATS TO AID GROWTH
7.5
CANINE PARVOVIRUS MONOCLONAL ANTIBODY (CPMA)
7.5.1
INCREASING ADOPTION OF CPMA BY VETERINARY CLINICS, SHELTERS, AND PET OWNERS TO SPUR MARKET
7.6.1
GROWING TREND TOWARD PERSONALIZED, TARGETED TREATMENTS TO FUEL MARKET
8
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 6 Data Tables
104
8.2
SUBCUTANEOUS ROUTE OF ADMINISTRATION
8.2.1
EASE OF ADMINISTRATION AND LOWER RISK OF TISSUE DAMAGE TO FACILITATE GROWTH
8.3
INTRAVENOUS ROUTE OF ADMINISTRATION
8.3.1
GROWING USE OF IV IN EMERGENCY CASES AND ONCOLOGY TO BOOST MARKET
8.4
ORAL ROUTE OF ADMINISTRATION
8.4.1
RISING INNOVATIONS IN LIVESTOCK APPLICATIONS TO ENCOURAGE GROWTH
9
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 6 Data Tables
110
9.2.1
FAVORABLE SAFETY PROFILE AND IMPROVED EFFICACY TO FOSTER GROWTH
9.3.1
RISING NEED FOR ALTERNATIVE DRUG DELIVERY TO AUGMENT GROWTH
9.4.1
GROWING FOCUS ON REDUCED HOSPITALIZATION TO DRIVE MARKET
9.5.1
INCREASING ADVANCEMENTS IN MONOCLONAL ANTIBODY THERAPIES TO ACCELERATE GROWTH
10
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 6 Data Tables
118
10.2
VETERINARY HOSPITALS/SPECIALTY CENTERS
10.2.1
RISE IN NUMBER OF VETERINARY SPECIALISTS TO SPEED UP GROWTH
10.3.1
GROWING PET OWNERSHIP AND PET CARE SPENDING TO FUEL MARKET
10.4
VETERINARY RESEARCH & ACADEMIC INSTITUTES
10.4.1
INCREASING COLLABORATIVE RESEARCH EFFORTS TO EXPEDITE GROWTH
11
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY REGION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million and Units | 144 Data Tables
127
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2.1
Strong R&D and early commercial adoption of monoclonal antibodies to drive market
11.2.3.1
Growing pet adoption to drive market
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2.1
Established veterinary infrastructure and high rate of pet ownership to aid growth
11.3.3.1
Growing companion animal population to drive market
11.3.4.1
Increasing pet ownership to drive the market
11.3.5.1
Strong demand for advanced therapies for companion animals and livestock to augment growth
11.3.6.1
Ongoing research in veterinary biologics to spur growth
11.3.7.1
Emerging pet care sector to contribute to growth
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2.1
Increasing awareness about pet health and well-established pet insurance system to drive market
11.4.3.1
Expanding pet market to fuel market
11.4.4.1
Growing pet adoption and veterinary shortage to drive market
11.4.5.1
Increased spending on veterinary care to support growth
11.4.6.1
Increasing awareness and adoption of preventive healthcare measures to drive market
11.4.7.1
Rising awareness of skin disorders to expedite growth
11.4.8
REST OF ASIA PACIFIC
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2.1
Expanding large-scale livestock operations to boost market
11.5.3.1
Increasing demand for targeted biologics in livestock and pets to drive market
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST & AFRICA
11.6.1
GROWING NUMBER OF COMPANION AND FOOD-PRODUCING ANIMALS TO PROPEL MARKET
11.6.2
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
12
COMPETITIVE LANDSCAPE
Discover strategic moves and market positioning of key players in veterinary monoclonal antibodies.
205
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET
12.3
REVENUE SHARE ANALYSIS, 2022–2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
BRAND/PRODUCT COMPARISON
12.6
COMPANY VALUATION AND FINANCIAL METRICS
12.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1
Company footprint
12.7.5.2
Region footprint
12.7.5.3
Animal type footprint
12.7.5.4
Route of administration footprint
12.7.5.5
Therapy area footprint
12.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1
PROGRESSIVE COMPANIES
12.8.2
RESPONSIVE COMPANIES
12.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.8.5.1
Detailed list of key startups/SMEs
12.8.5.2
Competitive benchmarking of key startups/SMEs
12.9
COMPETITIVE SCENARIO
12.9.1
PRODUCT LAUNCHES AND APPROVALS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
222
13.1.1
ZOETIS SERVICES LLC
13.1.1.1
Business overview
13.1.1.2
Products offered
13.1.1.3
Recent developments
13.2.1
VAXXINOVA INTERNATIONAL B.V.
13.2.6
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.2.9
NIPPON ZENYAKU KOGYO CO., LTD.
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
14.3.2
COMPANY INFORMATION
14.3.3
GEOGRAPHIC ANALYSIS
14.3.4
REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
14.3.5
COUNTRY-LEVEL VOLUME ANALYSIS
14.3.6
BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
14.3.7
ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
TABLE 1
VETERINARY MONOCLONAL ANTIBODIES MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
VETERINARY MONOCLONAL ANTIBODIES MARKET: RESEARCH ASSUMPTIONS
TABLE 3
VETERINARY MONOCLONAL ANTIBODIES MARKET: RISK ANALYSIS
TABLE 4
PET (DOGS AND CATS) OWNERSHIP IN US, 2024
TABLE 5
INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY KEY PLAYER, 2024 (USD)
TABLE 6
INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY REGION, 2022–2024 (USD)
TABLE 7
VETERINARY MONOCLONAL ANTIBODIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 8
VETERINARY MONOCLONAL ANTIBODIES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024
TABLE 9
IMPORT DATA FOR HS CODE 300214, BY COUNTRY, 2021–2024 (USD THOUSAND)
TABLE 10
EXPORT DATA FOR HS CODE 300214, BY COUNTRY, 2021–2024 (USD THOUSAND)
TABLE 11
VETERINARY MONOCLONAL ANTIBODIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 12
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15
VETERINARY MONOCLONAL ANTIBODIES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 16
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
TABLE 17
KEY BUYING CRITERIA, BY END USER
TABLE 18
VETERINARY MONOCLONAL ANTIBODIES MARKET: CURRENT UNMET NEEDS
TABLE 19
VETERINARY MONOCLONAL ANTIBODIES MARKET: PIPELINE ANALYSIS
TABLE 20
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 21
KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR VETERINARY MONOCLONAL ANTIBODIES MARKET
TABLE 22
IMPACT ON COUNTRY/REGION DUE TO US TARIFFS
TABLE 23
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 24
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR CANINES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 25
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR FELINES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 26
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER ANIMALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 27
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 28
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR LOKIVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR BEDINVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR FRUNEVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR CANINE PARVOVIRUS MONOCLONAL ANTIBODY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR GILVETMAB, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 34
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 35
COMMERCIALLY AVAILABLE MONOCLONAL ANTIBODIES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION
TABLE 36
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
COMMERCIALLY AVAILABLE MONOCLONAL ANTIBODIES WITH INTRAVENOUS ROUTE OF ADMINISTRATION
TABLE 38
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 41
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 47
AVERAGE TOTAL AMOUNT SPENT PER HOUSEHOLD ON PETS IN US, 2023–2024 (USD)
TABLE 48
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY HOSPITALS/SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51
VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 53
NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)
TABLE 54
NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 56
NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 57
NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 58
NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 59
NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 60
US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 61
US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 62
US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 63
US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 64
US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 65
CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 66
CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 67
CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 68
CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 69
CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 70
EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)
TABLE 71
EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION
TABLE 72
EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 73
EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 74
EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 75
EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 76
EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 77
GERMANY: KEY MACROECONOMIC INDICATORS
TABLE 78
GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 79
GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 80
GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 81
GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 82
GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 83
FRANCE: KEY MACROECONOMIC INDICATORS
TABLE 84
FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 85
FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 86
FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 87
FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 88
FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 89
UK: KEY MACROECONOMIC INDICATORS
TABLE 90
UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 91
UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 92
UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 93
UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 94
UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 95
ITALY: KEY MACROECONOMIC INDICATORS
TABLE 96
ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE 2023–2030 (USD MILLION)
TABLE 97
ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 98
ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 99
ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 100
ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 101
SPAIN: KEY MACROECONOMIC INDICATORS
TABLE 102
SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE 2023–2030 (USD MILLION)
TABLE 103
SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 104
SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 105
SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 106
SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 107
NETHERLANDS: KEY MACROECONOMIC INDICATORS
TABLE 108
NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 109
NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 110
NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 111
NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 112
NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 113
REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 114
REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 115
REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 116
REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 117
REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 118
ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)
TABLE 119
ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION
TABLE 120
ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 121
ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 122
ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 123
ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 124
ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 125
JAPAN: KEY MACROECONOMIC INDICATORS
TABLE 126
JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 127
JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 128
JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 129
JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 130
JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 131
CHINA: KEY MACROECONOMIC INDICATORS
TABLE 132
CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 133
CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 134
CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 135
CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 136
CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 137
INDIA: KEY MACROECONOMIC INDICATORS
TABLE 138
INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 139
INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 140
INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 141
INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 142
INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 143
AUSTRALIA: KEY MACROECONOMIC INDICATORS
TABLE 144
AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 145
AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 146
AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 147
AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 148
AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 149
SOUTH KOREA: KEY MACROECONOMIC INDICATORS
TABLE 150
SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 151
SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 152
SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 153
SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 154
SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 155
NEW ZEALAND: KEY MACROECONOMIC INDICATORS
TABLE 156
NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 157
NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 158
NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 159
NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 160
NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 161
REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 162
REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 163
REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 164
REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 165
REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 166
LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)
TABLE 167
LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168
LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 169
LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 170
LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 171
LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 172
LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 173
BRAZIL: KEY MACROECONOMIC INDICATORS
TABLE 174
BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 175
BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 176
BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 177
BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 178
BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 179
MEXICO: KEY MACROECONOMIC INDICATORS
TABLE 180
MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 181
MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 182
MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 183
MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 184
MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 185
REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 186
REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 187
REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 188
REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 189
REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 190
MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT)
TABLE 191
MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
TABLE 192
MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 193
MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
TABLE 194
MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION)
TABLE 195
MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 196
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET
TABLE 197
VETERINARY MONOCLONAL ANTIBODIES MARKET: DEGREE OF COMPETITION, 2024
TABLE 198
VETERINARY MONOCLONAL ANTIBODIES MARKET: REGION FOOTPRINT
TABLE 199
VETERINARY MONOCLONAL ANTIBODIES MARKET: ANIMAL TYPE FOOTPRINT
TABLE 200
VETERINARY MONOCLONAL ANTIBODIES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
TABLE 201
VETERINARY MONOCLONAL ANTIBODIES MARKET: THERAPY AREA FOOTPRINT
TABLE 202
VETERINARY MONOCLONAL ANTIBODIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 203
VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 204
VETERINARY MONOCLONAL ANTIBODIES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025
TABLE 205
VETERINARY MONOCLONAL ANTIBODIES MARKET: DEALS, JANUARY 2022–JUNE 2025
TABLE 206
VETERINARY MONOCLONAL ANTIBODIES MARKET: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 207
ZOETIS SERVICES LLC: COMPANY OVERVIEW
TABLE 208
ZOETIS SERVICES LLC: PRODUCTS OFFERED
TABLE 209
ZOETIS SERVICES LLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022−JUNE 2025
TABLE 210
ZOETIS SERVICES LLC: DEALS, JANUARY 2022−JUNE 2025
TABLE 211
ELANCO: COMPANY OVERVIEW
TABLE 212
ELANCO: PRODUCTS OFFERED
TABLE 213
ELANCO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022−JUNE 2025
TABLE 214
ELANCO: EXPANSIONS, JANUARY 2022−JUNE 2025
TABLE 215
MERCK & CO., INC.: COMPANY OVERVIEW
TABLE 216
MERCK & CO., INC.: PRODUCTS OFFERED
TABLE 217
MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022−JUNE 2025
TABLE 218
MERCK & CO., INC.: EXPANSIONS, JANUARY 2022−JUNE 2025
TABLE 219
ANIMAB: COMPANY OVERVIEW
TABLE 220
ANIMAB: PRODUCTS OFFERED
TABLE 221
ANIMAB: DEALS, JANUARY 2022−JUNE 2025
TABLE 222
VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW
TABLE 223
CEVA LOGISTICS: COMPANY OVERVIEW
TABLE 224
MABGENESIS INC.: COMPANY OVERVIEW
TABLE 225
DECHRA: COMPANY OVERVIEW
TABLE 226
BIOGENESIS BAGO: COMPANY OVERVIEW
TABLE 227
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
TABLE 228
VIRBAC: COMPANY OVERVIEW
TABLE 229
BIOVETA, A.S.: COMPANY OVERVIEW
TABLE 230
NIPPON ZENYAKU KOGYO CO., LTD.: COMPANY OVERVIEW
FIGURE 1
VETERINARY MONOCLONAL ANTIBODIES MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2
VETERINARY MONOCLONAL ANTIBODIES MARKET: YEARS CONSIDERED
FIGURE 3
VETERINARY MONOCLONAL ANTIBODIES MARKET: RESEARCH DESIGN
FIGURE 4
VETERINARY MONOCLONAL ANTIBODIES MARKET: KEY PRIMARY SOURCES
FIGURE 5
VETERINARY MONOCLONAL ANTIBODIES MARKET: INSIGHTS FROM PRIMARIES
FIGURE 6
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 7
BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 8
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION
FIGURE 9
VETERINARY MONOCLONAL ANTIBODIES MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024
FIGURE 10
MONOCLONAL ANTIBODIES IN ANIMAL HEALTH: MARKET SIZE ESTIMATION
FIGURE 11
TOP-DOWN APPROACH
FIGURE 12
BOTTOM-UP APPROACH
FIGURE 13
VETERINARY MONOCLONAL ANTIBODY MARKET: CAGR PROJECTIONS
FIGURE 14
DATA TRIANGULATION METHODOLOGY
FIGURE 15
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 16
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
FIGURE 17
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
FIGURE 18
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2025 VS. 2030 (USD MILLION)
FIGURE 19
VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 20
GEOGRAPHICAL SNAPSHOT OF VETERINARY MONOCLONAL ANTIBODIES MARKET
FIGURE 21
INCREASING PREVALENCE OF CHRONIC AND ACUTE DISEASES TO DRIVE MARKET
FIGURE 22
CANINES SEGMENT AND US LED NORTH AMERICA MARKET IN 2024
FIGURE 23
CANINES SEGMENT TO CAPTURE LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 24
LOKIVETMAB (CYTOPOINT) SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 25
SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 26
DERMATOLOGY SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 27
FRANCE TO REGISTER HIGHEST GROWTH IN VETERINARY MONOCLONAL ANTIBODIES MARKET FROM 2025 TO 2030
FIGURE 28
VETERINARY MONOCLONAL ANTIBODIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 29
NEW REVENUE POCKETS FOR PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET
FIGURE 30
VETERINARY MONOCLONAL ANTIBODIES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 31
VETERINARY MONOCLONAL ANTIBODIES MARKET: ECOSYSTEM ANALYSIS
FIGURE 32
VETERINARY MONOCLONAL ANTIBODIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2020–2024
FIGURE 33
VETERINARY MONOCLONAL ANTIBODIES MARKET: PATENT ANALYSIS, JANUARY 2014–MAY 2025
FIGURE 34
TOP APPLICANTS FOR VETERINARY MONOCLONAL ANTIBODIES PATENTS, JANUARY 2014–MAY 2025
FIGURE 35
VETERINARY MONOCLONAL ANTIBODIES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 36
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
FIGURE 37
KEY BUYING CRITERIA, BY END USER
FIGURE 38
VETERINARY MONOCLONAL ANTIBODIES MARKET: AI USE CASES
FIGURE 39
NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET SNAPSHOT
FIGURE 40
ASIA PACIFIC: DOG POPULATION GROWTH, BY COUNTRY, 2024
FIGURE 41
ASIA PACIFIC: CAT POPULATION GROWTH, BY COUNTRY, 2024
FIGURE 42
REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET, 2023–2024
FIGURE 43
VETERINARY MONOCLONAL ANTIBODIES MARKET SHARE ANALYSIS, 2024
FIGURE 44
US: VETERINARY MONOCLONAL ANTIBODIES MARKET SHARE ANALYSIS, 2024
FIGURE 45
RANKING OF KEY PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET, 2024
FIGURE 46
VETERINARY MONOCLONAL ANTIBODIES MARKET: BRAND/PRODUCT COMPARISON
FIGURE 47
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 48
EV/EBITDA OF KEY VENDORS
FIGURE 49
VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 50
VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY FOOTPRINT
FIGURE 51
VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 52
ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2024)
FIGURE 53
ELANCO: COMPANY SNAPSHOT (2024)
FIGURE 54
MERCK & CO., INC.: COMPANY SNAPSHOT (2024)
Growth opportunities and latent adjacency in Veterinary Monoclonal Antibodies Market